The subject of this publication is the conclusion of agreements pursuant to Section 130a (8) SGB V on various active substances / combinations of active substances in the context of an open house procedure. For details, see the relevant lot.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / active ingredient combinations within the framework of a so-called open house process. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the possibility of concluding or joining a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete free access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following e-mail address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is February 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. At the start of the contract on February 1, 2021, the offer must be available by December 23, 2020, but AOK Nordost will not conclude any contracts before January 4, 2021. For a later start of the contract, the submission deadline for offers is the 5th of the previous month. (Example: contract start March 1st, 2021; deadline for submitting the offer: February 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the contract period as part of an open procedure, the contractual provisions concluded in this publication apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation open procedure, are only owed to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.